Navigation Links
LAB Research announces changes to its Board of Directors
Date:2/9/2009

www.labresearch.com

Toronto Stock Exchange Symbol: LRI

LAVAL, QC, Feb. 9 /PRNewswire-FirstCall/ - LAB Research Inc. ("LRI", "LAB Research" or the "Company") (TSX: LRI), a Canadian-based global non-clinical contract research organization, today announced the nomination of Mr. Carl A. Spalding as Chairman of its Board of Directors in replacement of Mr. Karsten Skydsgaard who previously communicated a wish to step down of the Board to focus on his other professional obligations.

"On behalf of the Board of Directors, I would like to thank Karsten for his dedication and contribution to LAB Research since our 2006 Initial Public Offering ("IPO"). His expertise, and continuous support toward the Company have played a key role in LRI's development and success," said Mr. Luc Mainville, Chief Executive Officer and President of LAB Research.

Mr. Spalding brings to LRI extensive operational experience and contacts in the global pharmaceutical and contract research organization industries. Mr. Spalding has held numerous senior executive positions such as President and Chief Operating Officer of PAREXEL International Corporation, Executive Vice President and Group President, Healthcare Products Services at Cardinal Health and Vice President and General Manager, Ross Products for Abbott Laboratories.

"I am impressed with the timely execution and completion of the growth and development strategy put forward by the Senior Management team at LRI since its 2006 IPO. I am also confident that the recently adopted measures to insure a swift improvement of the Company's financial performance will prove to be successful and look forward to actively participating in the continued success of LAB Research," commented Mr. Spalding.

"We are very fortunate to have someone of Carl's calibre and with such industry experience and relationships to assume the Chairmanship of LAB Research. Now that we have completed our expansion program and are positioned to benefit from the significant revenue capacity added, we will greatly benefit from Carl's strong global operational background and business insight as we strive towards improving our profitability and overall financial performance," added Mr. Luc Mainville.

About LAB Research Inc.:

LAB Research is a Canadian global non-clinical contract research organization that provides contract research services to the pharmaceutical, biotechnology, agro-chemical, petro-chemical and industrial markets. LAB Research supports the development of its customers' products from three state-of-the-art facilities located in Canada, Denmark and Hungary.

LAB Research's shares trade on The Toronto Stock Exchange ("TSX") under the symbol "LRI", with 18.1 million shares outstanding.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of LAB Research Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.


'/>"/>
SOURCE LAB RESEARCH INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Artemis Health Hires Richard Rava, Ph.D., as Senior Vice President of Research and Development
2. LAB research to present at upcoming UBS 2009 global healthcare services conference in New York
3. In Analyst Interview, Cord Blood America Says Stem Cells Now Front and Center for Researchers and Investors
4. Heinlein Trust and SpaceX Announce Competition to Promote Research Innovation in Zero Gravity
5. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
6. Eric Lai Joins Gen-Probe as Senior Vice President, Research and Development
7. ERT (eResearchTechnology, Inc.) and Integrium, LLC Form Alliance to Deliver Integrated Cardiac Safety and Ambulatory Blood Pressure Monitoring Services
8. 23andMe and mondoBIOTECH Partner to Advance Research of Rare Diseases
9. Clinical Research Study Focuses on Little Known Behavioral Changes Related to Parkinsons Disease
10. NewCardio Joins the Cardiac Safety Research Consortium
11. Avantium Launches the Crystalline, a New Parallel System for Crystallization Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... ... (PRWEB) May 16, 2017 , ... ... Chinese Association of Orthopaedic Surgeons (CAOS), long-standing development partners Invibio Biomaterial Solutions, ... interbody spine surgery workshop to help expand knowledge of the implantation of ...
(Date:5/15/2017)... ... May 15, 2017 , ... ... Advanced Lift Contouring Cream, a gravity-shattering cream with a patented formula, clinically proven ... to bring the Advanced Lift Contouring Cream to our already innovative ELEVATE product ...
(Date:5/12/2017)... May 12, 2017  Eli Lilly and Company (NYSE: ... an investigational treatment for the prevention of episodic ... three Phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) ... monthly migraine headache days compared to placebo at ... results from these three studies bring us one ...
(Date:5/11/2017)... ... 2017 , ... The key to unlocking the cause of Multiple Sclerosis may ... neurological disorder that can rob people of their ability to see, speak, and walk. ... arises from a genetic tendency towards the disease combined with an unidentified environmental trigger. ...
Breaking Biology Technology:
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
Breaking Biology News(10 mins):